Capstone Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Capstone Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,171	Closed	-$494K	–	1936
2025 Q3	$494K	Buy	+19,171	New	+$471K	﹤0.01%	1384
2024 Q3	–	Sell	-7,168	Closed	-$205K	–	2123
2024 Q2	$205K	Sell	7,168 -3,581	-33%	-$102K	﹤0.01%	1762
2024 Q1	$314K	Buy	+10,749	New	+$330K	﹤0.01%	1811
2023 Q4	–	Sell	-7,073	Closed	-$217K	–	2327
2023 Q3	$217K	Buy	+7,073	New	+$255K	﹤0.01%	1774
2016 Q4	–	Sell	-6,000	Closed	-$205K	–	1068
2016 Q3	$205K	Buy	+6,000	New	+$235K	﹤0.01%	682

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capstone Investment Advisors's PCRX Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 19,171 shares — an estimated $494K sold.

Capstone Investment Advisors first reported a position in PCRX in Q3 2016 and held it in 5 quarters. The position peaked at $494K in Q3 2025. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Capstone Investment Advisors reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
Capstone Investment Advisors sold 19,171 Pacira BioSciences shares in Q4 2025, an estimated $494K.
Capstone Investment Advisors first reported a position in Pacira BioSciences in Q3 2016 and held it in 5 quarters.
Capstone Investment Advisors's Pacira BioSciences position peaked at $494K in Q3 2025.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.